- Home
- NUWE vs IXHL Comparison
NUWE vs IXHL Comparison
Compare NUWE & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- IXHL
- Stock Information
- Founded
- NUWE 1999
- IXHL 2001
- Country
- NUWE United States
- IXHL Australia
- Employees
- NUWE N/A
- IXHL N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IXHL
- Sector
- NUWE Health Care
- IXHL
- Exchange
- NUWE Nasdaq
- IXHL Nasdaq
- Market Cap
- NUWE 3.9M
- IXHL 3.6M
- IPO Year
- NUWE N/A
- IXHL N/A
- Fundamental
- Price
- NUWE $0.40
- IXHL $0.18
- Analyst Decision
- NUWE Strong Buy
- IXHL
- Analyst Count
- NUWE 1
- IXHL 0
- Target Price
- NUWE $17.00
- IXHL N/A
- AVG Volume (30 Days)
- NUWE 187.8K
- IXHL 146.9M
- Earning Date
- NUWE 05-13-2025
- IXHL 05-15-2025
- Dividend Yield
- NUWE N/A
- IXHL N/A
- EPS Growth
- NUWE N/A
- IXHL N/A
- EPS
- NUWE N/A
- IXHL N/A
- Revenue
- NUWE $8,787,000.00
- IXHL $98,000.00
- Revenue This Year
- NUWE $26.81
- IXHL $3,817.06
- Revenue Next Year
- NUWE $48.74
- IXHL $66.67
- P/E Ratio
- NUWE N/A
- IXHL N/A
- Revenue Growth
- NUWE N/A
- IXHL N/A
- 52 Week Low
- NUWE $0.40
- IXHL $0.08
- 52 Week High
- NUWE $8.40
- IXHL $3.55
- Technical
- Relative Strength Index (RSI)
- NUWE 15.96
- IXHL 42.72
- Support Level
- NUWE $0.76
- IXHL $0.18
- Resistance Level
- NUWE $0.95
- IXHL $0.21
- Average True Range (ATR)
- NUWE 0.09
- IXHL 0.03
- MACD
- NUWE -0.05
- IXHL 0.01
- Stochastic Oscillator
- NUWE 0.00
- IXHL 6.64
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.